Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug works best for cirrhosis patients with bleeding and kidney trouble?

NCT ID NCT07252401

Disease control Sponsor: General Hospital of Shenyang Military Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This study compares two drugs, terlipressin and somatostatin, in 64 adults with liver cirrhosis who have acute gastrointestinal bleeding and acute kidney injury. Both drugs are given intravenously for up to 5 days. The main goal is to see which drug better reverses kidney injury. This is a randomized controlled trial, meaning patients are assigned to one drug or the other by chance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
terlipressin (also known as Terlivaz) and somatostatin (also known as Stilamin)
What this could lead to
If terlipressin proves better, it could become the preferred treatment for cirrhosis patients with both bleeding and kidney injury, potentially improving outcomes.
What could go wrong
This is a small, early-stage trial with only 64 participants, so results may not apply to all patients. The treatment is short-term (5 days) and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients have a definite diagnosis of live cirrhosis and AVB; * patients present with renal dysfunction at admission; * patients' age 18-70 years old; * patients or relatives can sign the informed consent form. Exclusion Criteria: * patients have non-variceal upper gastrointestinal bleeding; * patients have hepatorenal syndrome- acute renal injury (HRS-AKI); * patients have structural kidney injury; * patients have chronic kidney disease; * patients received kidney replacement therapy before enrollment; * patients have a history of liver transplantation or TIPS; * patients have acute liver failure or acute-on-chronic liver failure; * patients have hepatic or renal malignant tumor; * patients have severe diseases of the heart, lungs, and brain; * patients have contraindications for experimental drugs; * patients are in pregnancy or lactation; * patients participated in other clinical studies within 3 months before enrollment; * patients have other conditions that investigators deem unsuitable for enrollment in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute variceal bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury cirrhosis of liver esophageal varices with bleeding kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)

    Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.